Recent Finacing
Recent Raise
Immunovant develops IMVT-1401, a subcutaneous fully human anti‑FcRn monoclonal antibody that lowers IgG and albumin, and conducts pivotal and mid‑stage clinical trials in myasthenia gravis, WAIHA, and TED.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Immunovant.
